UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________________
FORM 8-K
_______________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 3, 2023
_________________________
(Exact Name of Registrant as Specified in Its Charter)
_________________________
(State or other jurisdiction of incorporation or organization) | (Commission File No.) | (I.R.S. Employer Identification No.) | |||||||||
(Address of Principal Executive Offices) | (Zip Code) | ||||||||||
(571 ) 366-8850
Registrant's telephone number, including area code
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)
Check the appropriate box below if the form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
| Emerging growth company | |||||||||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On November 3, 2023, Privia Health Group, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2023. A copy of the press release is attached hereto as Exhibit 99.1.
The text of the press release is incorporated by reference into this Item 2.02. The press release being “furnished” pursuant to this Item 2.02 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section 18, and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in any such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibit:
| Exhibit No. | Description | |||||||
| 99.1 | ||||||||
| 104 | The Cover Page from this Current Report on Form 8-K, Interactive Data File (formatted as Inline XBRL) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| PRIVIA HEALTH GROUP, INC. | |||||||||||
Date: November 3, 2023 | By: | /s/ David Mountcastle | |||||||||
| Name: David Mountcastle | |||||||||||
| Title: Executive Vice President, Chief Financial Officer and Authorized Officer | |||||||||||
 | Exhibit 99.1 | |||||||||||||
Privia Health Reports Third Quarter 2023 Financial Results; Announces New Market Entry in South Carolina
–Practice Collections +18.2% compared to 3Q’22
–Implemented Providers +14.2% compared to 3Q’22
–Company Updated Full Year 2023 Guidance
ARLINGTON, VA – November 3, 2023 – Privia Health Group, Inc. (Nasdaq: PRVA) today announced financial results for the third quarter and nine month periods ended September 30, 2023.
Third Quarter
Total revenue for the third quarter of 2023 was $417.3 million, compared to total revenue of $342.9 million for the prior year third quarter (+21.7%). Gross Profit for the third quarter of 2023 was $90.6 million, compared to $76.9 million for the prior year third quarter. Operating income for the third quarter of 2023 was $5.5 million, compared to operating loss of $(4.6) million for the prior year third quarter. Net income for the third quarter of 2023 was $5.6 million, or $0.05 per share, compared to net income of $1.6 million, or $0.01 per share, for the third quarter of 2022. Net income for the third quarter of 2023 included $10.8 million in non-cash stock compensation expense and $0.7 million in other expenses. Net income for the third quarter of 2022 included $14.8 million in non-cash stock compensation expense and $4.2 million in other expenses.
Non-GAAP adjusted net income was $21.1 million, or $0.17 per diluted share, for the third quarter of 2023, compared to $16.7 million, or $0.13 per diluted share, for the prior year third quarter (+26.3%).
Reconciliation of net income (loss) to adjusted net income, as well as other non-GAAP reconciliations, are presented in tables near the end of this press release.
Key operating and non-GAAP financial metrics include:
•Practice Collections for the third quarter of 2023 were $723.5 million, compared to $611.9 million for the same period in 2022 (+18.2%).
•Care Margin for the third quarter of 2023 was $92.1 million, compared to $77.7 million for the same period in 2022 (+18.4%).
•Platform Contribution for the third quarter of 2023 was $45.2 million, compared to $37.0 million for the same period in 2022 (+22.2%).
•Adjusted EBITDA for the third quarter of 2023 was $18.8 million, compared to $15.7 million for the same period in 2022 (+20.0%).
•Implemented Providers for the third quarter of 2023 were 4,105, compared to 3,595 for the same period in 2022 (+14.2%).
•Value-Based Care Attributed Lives for the third quarter of 2023 were approximately 1,094,000, compared to 846,000 for the same period in 2022 (+29.3%).
1
Nine Months
Total revenue was $1.22 billion for the nine months ended September 30, 2023, an increase from $992.2 million for the same period in 2022 (+22.6%). Operating income for the first nine months of 2023 was $19.2 million, compared to operating loss of $(21.4) million for the same period in 2022.
Net income for the first nine months of 2023 was $20.2 million, or $0.16 per diluted share, compared to net loss of $(26.4) million, or $(0.24) per diluted share, for the same period in 2022. Excluding non-cash or non-recurring expenses, non-GAAP adjusted net income for the first nine months of 2023 was $61.1 million, or $0.49 per diluted share, compared to non-GAAP adjusted net income of $47.6 million, or $0.39 per diluted share, for the first nine months of 2022 (+28.4%).
Key operating and non-GAAP financial metrics include:
•Practice Collections for the first nine months of 2023 were $2.08 billion, compared to $1.79 billion for the same period in 2022 (+16.4%).
•Care Margin for the first nine months of 2023 was $267.7 million, compared to $225.6 million for the same period in 2022 (+18.7%).
•Platform Contribution for the first nine months of 2023 was $131.2 million, compared to $109.5 million for the same period in 2022 (+19.9%).
•Adjusted EBITDA for the first nine months of 2023 was $55.0 million, compared to $46.6 million for the same period in 2022 (+18.0%).
Privia Enters South Carolina
Privia Health today announced it is entering South Carolina in partnership with Greenville ENT and Allergy Associates (GENTA), a practice with approximately 20 providers. GENTA will serve as the anchor partner for Privia Medical Group South Carolina, and is expected to be implemented in the first half of 2024.
Capital Resources
The Company's balance sheet at September 30, 2023, included cash and cash equivalents of $330.4 million and no debt. This does not include $91.2 million in cash received in October 2023 from the Centers for Medicare and Medicaid Services (CMS) as payment for Privia Health’s portion of the shared savings generated in the 2022 performance year of the Medicare Shared Savings Program (MSSP). At December 31, 2022, the Company’s balance sheet included $348.0 million of cash and cash equivalents and no debt.
Financial and Business Outlook a b c d
Privia Health updated its full-year 2023 guidance, as follows:
| FY 2022 | Initial FY 2023 Guidance at 2.28.23 a | Current FY 2023 Guidance 11.3.23 | ||||||||||||||||||||||||
| ($ in millions) | Actual | Low | High | |||||||||||||||||||||||
Implemented Providers | 3,606 | 4,050 | 4,150 | Above High End | ||||||||||||||||||||||
Attributed Lives | 856,000 | 1,050,000 | 1,150,000 | Midpoint | ||||||||||||||||||||||
Practice Collections | $ | 2,424.1 | $ | 2,700 | $ | 2,850 | Midpoint | |||||||||||||||||||
GAAP Revenue | $ | 1,356.7 | $ | 1,550 | $ | 1,650 | Mid to High End | |||||||||||||||||||
Care Margin | $ | 305.6 | $ | 350 | $ | 365 | Mid to High End | |||||||||||||||||||
Platform Contribution | $ | 148.5 | $ | 160 | $ | 168 | Above High End | |||||||||||||||||||
Adjusted EBITDAc | $ | 60.9 | $ | 70 | $ | 74 | Mid to High End | |||||||||||||||||||
2
•Practice Collections guidance includes impact of paused capitated agreement previously announced
•Adjusted EBITDA guidance includes approximately $10 million in start-up costs for new geographies and ACOs, and higher than initially forecasted sales and marketing costs due to record in-market sales
•Capital expenditures expected to be less than $1 million in full-year 2023
•Approximately 80-90% of Adjusted EBITDA expected to convert to free cash flow (defined as net cash provided by operating activities less capital expenditures) in FY 2023
a.Management has not reconciled forward-looking non-GAAP measures to their most directly comparable GAAP measures of gross margin, operating income and net income. This is because the Company cannot predict with reasonable certainty and without unreasonable efforts the ultimate outcome of certain GAAP components of such reconciliations due to market-related assumptions that are not within our control as well as certain legal or advisory costs, tax costs or other costs that may arise. For these reasons, management is unable to assess the probable significance of the unavailable information, which could materially impact the amount of the future directly comparable GAAP measures.
b.See “Key Metrics and Non-GAAP Financial Measures” for more information as to how the Company defines and calculates Implemented Providers, Attributed Lives, Practice Collections, Care Margin, Platform Contribution, and Adjusted EBITDA, and for a reconciliation of the most comparable GAAP measures to Care Margin, Platform Contribution, Adjusted EBITDA, Adjusted Net Income and Adjusted Net Income Per Share.
c.Certain non-recurring or non-cash and other expenses will be treated as an add back in the reconciliation of Net Income to Adjusted EBITDA, and the reconciliation of Net Income to Adjusted Net Income and Adjusted Net Income Per Share, the details of which can be found in the Reconciliation schedules near the end of this and in future quarterly financial press releases.
d.Any slight variations in totals due to rounding.
Webcast and Conference Call Information
The Company will host a conference call on November 3, 2023, at 8:00 am ET to discuss these results and management’s outlook for future financial and operational performance. You can visit ir.priviahealth.com/news-and-events/events-and-presentations to listen to the call via live webcast. The webcast will be archived and available for replay for on-demand listening shortly after the completion of the call under the same link. If you wish to participate in the live conference call, then please go to https://register.vevent.com/register/BI93f79e2535cf432ab5d86149b9f61609 to pre-register and obtain your dial-in number and passcode.
This news release and the financial statements contained herein, and the slide presentation for the webcast, are also available on the Privia Health Investor Relations website at ir.priviahealth.com.
About Privia Health
Privia Health™ is a technology-driven, national physician enablement company that collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual settings. Our platform is led by top industry talent and exceptional physician leadership, and consists of scalable operations and end-to-end, cloud-based technology that reduces unnecessary healthcare costs, achieves better outcomes, and improves the health of patients and the well-being of providers. For more information, visit priviahealth.com.
Non-GAAP Financial Measures
The Company reports and discusses its operating results using financial measures consistent with accounting principles generally accepted in the United States ("GAAP"). From time to time, in press releases, financial presentations, earnings conference calls or otherwise, the Company may disclose certain non-GAAP financial measures. The non-GAAP financial measures presented in this press release should
3
not be viewed as alternatives or substitutes for the Company's reported GAAP results. A reconciliation to the most directly comparable GAAP financial measure is set forth in the tables that accompany this release.
The Company believes that the non-GAAP financial measures presented in this press release are relevant and provide useful information to the Company's management, investors, and other interested parties about the Company's operating performance because the measures allow them to understand and compare the Company's actual and expected operating results during the prior, current and future periods in a more consistent manner. The non-GAAP measures presented in this press release may not be comparable to similarly titled measures used by other companies. These non-GAAP financial measures are used in addition to and in conjunction with results presented in accordance with GAAP and reflect an additional way of viewing aspects of the Company's operations that, when viewed with GAAP results and the accompanying reconciliations to corresponding GAAP financial measures, provides a more complete understanding of the results of operations and trends affecting the Company's business. These non-GAAP financial measures should be considered as a supplement to, and not as a substitute for, or superior to financial measures calculated in accordance with GAAP.
Safe Harbor Statement
The financial results in this press release reflect preliminary, unaudited results, which are not final until the Company’s Form 10-Q is filed with the Securities and Exchange Commission (“SEC”). This press release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such statements relate to our current expectations, projections and assumptions about our business, the economy and future events or conditions. They do not relate strictly to historical or current facts. Forward-looking statements can be identified by words such as “aims,” “anticipates,” "assumes," “believes,” “estimates,” “expects,” “forecasts,” “future,” “intends,” “likely,” “may,” “outlook,” “plans,” “potential,” “projects,” “seeks,” “strategy,” “targets,” “trends,” “will,” “would,” “could,” “should,” and variations of such terms and similar expressions and references to guidance, although some forward-looking statements may be expressed differently. In particular, these include statements relating to, among other things: our future actions, business plans, objectives and prospects; and our future operating or financial performance and projections, including our full year guidance for 2022. Factors or events that could cause actual results to differ may emerge from time to time and are difficult to predict. Should known or unknown risks or uncertainties materialize, or should underlying assumptions prove inaccurate, actual results may differ materially from past results and those anticipated, estimated or projected. We caution you not to place undue reliance upon any of these forward-looking statements.
Factors related to these risks and uncertainties include, but are not limited to: compliance with applicable healthcare laws and government regulations in the heavily regulated industry in which the Company operates; the Company’s dependence on relationships with its medical groups, some of which the Company does not own; the Company’s growth strategy, which may not prove viable and the Company may not realize expected results; the Company’s inability to successfully enter new markets; difficulties implementing the Company’s proprietary end-to-end, cloud-based technology solution for Privia physicians and new medical groups; the high level of competition in the Company’s industry and the Company’s failure to compete and innovate; challenges in successfully establishing a presence in new geographic markets; the Company’s reliance on its electronic medical record vendor, which the Privia Technology Solution is integrated and built upon; changes in the payer mix of patients and potential decreases in the Company’s reimbursement rates as a result of consolidation among commercial payers; the Company’s use, disclosure, and other processing of personally identifiable information, including health information, is subject to the Health Insurance Portability and Accountability Act of 1996 and other federal and state privacy and security regulations; and those factors discussed under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022 and the Company’s
4
subsequent Quarterly Reports on Form 10-Q. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.
| Contact: | ||
| Robert Borchert | ||
| SVP, Investor & Corporate Communications | ||
| IR@priviahealth.com | ||
| 817.783.4841 | ||
5
Privia Health Group, Inc.
Condensed Consolidated Statements of Operations(a)
(unaudited)
(in thousands, except share and per share data)
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | ||||||||||||||||||||||
| 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||
| Revenue | $ | 417,282 | $ | 342,899 | $ | 1,216,909 | $ | 992,236 | |||||||||||||||
| Operating expenses: | |||||||||||||||||||||||
| Provider expense | 325,222 | 265,174 | 949,195 | 766,672 | |||||||||||||||||||
| Cost of platform | 50,324 | 43,839 | 145,254 | 127,495 | |||||||||||||||||||
| Sales and marketing | 7,241 | 5,088 | 18,483 | 14,568 | |||||||||||||||||||
| General and administrative | 27,228 | 32,219 | 79,987 | 101,436 | |||||||||||||||||||
| Depreciation and amortization | 1,731 | 1,153 | 4,761 | 3,436 | |||||||||||||||||||
| Total operating expenses | 411,746 | 347,473 | 1,197,680 | 1,013,607 | |||||||||||||||||||
| Operating income (loss) | 5,536 | (4,574) | 19,229 | (21,371) | |||||||||||||||||||
| Interest (income) expense, net | (2,894) | (285) | (5,524) | 610 | |||||||||||||||||||
Income (loss) before provision for (benefit from) income taxes | 8,430 | (4,289) | 24,753 | (21,981) | |||||||||||||||||||
Provision for (benefit from) income taxes | 2,488 | (4,845) | 6,049 | 6,931 | |||||||||||||||||||
| Net income (loss) | 5,942 | 556 | 18,704 | (28,912) | |||||||||||||||||||
Gain (loss) attributable to non-controlling interests | 299 | (1,068) | (1,537) | (2,551) | |||||||||||||||||||
| Net income (loss) attributable to Privia Health Group, Inc. | $ | 5,643 | $ | 1,624 | $ | 20,241 | $ | (26,361) | |||||||||||||||
| Net income (loss) per share attributable to Privia Health Group, Inc. stockholders – basic | $ | 0.05 | $ | 0.01 | $ | 0.17 | $ | (0.24) | |||||||||||||||
| Net income (loss) per share attributable to Privia Health Group, Inc. stockholders – diluted | $ | 0.05 | $ | 0.01 | $ | 0.16 | $ | (0.24) | |||||||||||||||
| Weighted average common shares outstanding – basic | 117,602,059 | 111,592,834 | 116,266,938 | 109,458,855 | |||||||||||||||||||
| Weighted average common shares outstanding – diluted | 124,924,442 | 124,845,602 | 124,646,849 | 109,458,855 | |||||||||||||||||||
(a) Any slight variations in totals due to rounding.
6
Privia Health Group, Inc.
Condensed Consolidated Balance Sheets(a)
(in thousands)
| September 30, 2023 | December 31, 2022 | ||||||||||
| Assets | (unaudited) | ||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 330,391 | $ | 347,992 | |||||||
| Accounts receivable | 350,110 | 189,604 | |||||||||
| Prepaid expenses and other current assets | 17,167 | 14,366 | |||||||||
| Total current assets | 697,668 | 551,962 | |||||||||
| Non-current assets: | |||||||||||
| Property and equipment, net | 2,597 | 3,386 | |||||||||
| Right-of-use asset | 7,104 | 8,089 | |||||||||
| Intangible assets, net | 107,244 | 57,387 | |||||||||
| Goodwill | 135,612 | 126,938 | |||||||||
| Deferred tax asset | 35,189 | 40,368 | |||||||||
| Other non-current assets | 6,916 | 4,683 | |||||||||
| Total non-current assets | 294,662 | 240,851 | |||||||||
| Total assets | $ | 992,330 | $ | 792,813 | |||||||
| Liabilities and stockholders’ equity | |||||||||||
| Current liabilities: | |||||||||||
| Accounts payable and accrued expenses | $ | 54,326 | $ | 52,837 | |||||||
| Provider liability | 336,641 | 208,424 | |||||||||
| Operating lease liabilities, current | 3,225 | 3,013 | |||||||||
| Total current liabilities | 394,192 | 264,274 | |||||||||
| Non-current liabilities: | |||||||||||
| Operating lease liabilities, non-current | 5,768 | 8,490 | |||||||||
| Other non-current liabilities | 1,313 | 1,000 | |||||||||
| Total non-current liabilities | 7,081 | 9,490 | |||||||||
| Total liabilities | 401,273 | 273,764 | |||||||||
| Commitments and contingencies | |||||||||||
| Stockholders’ equity: | |||||||||||
| Common stock | 1,180 | 1,148 | |||||||||
| Additional paid-in capital | 739,953 | 714,639 | |||||||||
| Accumulated deficit | (196,452) | (216,693) | |||||||||
| Total Privia Health Group, Inc. stockholders’ equity | 544,681 | 499,094 | |||||||||
| Non-controlling interest | 46,376 | 19,955 | |||||||||
| Total stockholders’ equity | 591,057 | 519,049 | |||||||||
| Total liabilities and stockholders’ equity | $ | 992,330 | $ | 792,813 | |||||||
(a) Any slight variations in totals are due to rounding.
7
Privia Health Group, Inc.
Condensed Consolidated Statements of Cash Flows(a)
(unaudited)
(in thousands)
| For the Nine Months Ended September 30, | |||||||||||
| 2023 | 2022 | ||||||||||
| Cash flows from operating activities | |||||||||||
| Net income (loss) | $ | 18,704 | $ | (28,912) | |||||||
| Adjustments to reconcile net income (loss) to net cash used in operating activities: | |||||||||||
| Depreciation | 878 | 927 | |||||||||
| Amortization of intangibles | 3,883 | 2,509 | |||||||||
| Amortization of debt issuance costs | — | 687 | |||||||||
| Stock-based compensation | 25,429 | 58,184 | |||||||||
| Deferred tax expense | 5,179 | 6,553 | |||||||||
| Changes in asset and liabilities: | |||||||||||
| Accounts receivable | (156,219) | (128,946) | |||||||||
| Prepaid expenses and other current assets | (2,801) | 1,657 | |||||||||
| Other non-current assets and right-of-use asset | (1,246) | (7,705) | |||||||||
| Accounts payable and accrued expenses | 1,489 | 1,268 | |||||||||
| Provider liability | 123,930 | 113,570 | |||||||||
| Operating lease liabilities | (2,510) | (1,750) | |||||||||
| Other long-term liabilities | (32) | — | |||||||||
Net cash provided by operating activities | 16,684 | 18,042 | |||||||||
| Cash from investing activities | |||||||||||
| Purchases of property and equipment | (90) | (89) | |||||||||
| Business Acquisitions, net of cash acquired | (37,858) | — | |||||||||
| Net cash used in investing activities | (37,948) | (89) | |||||||||
| Cash flows from financing activities | |||||||||||
| Repayment of note payable | — | (33,250) | |||||||||
| Proceeds from exercised stock options | 8,788 | 11,491 | |||||||||
| Repurchase of non-controlling interest | (5,694) | — | |||||||||
| Proceeds from non-controlling interest | 569 | 125 | |||||||||
Net cash provided by (used in) financing activities | 3,663 | (21,634) | |||||||||
| Net decrease in cash and cash equivalents | (17,601) | (3,681) | |||||||||
| Cash and cash equivalents at beginning of period | 347,992 | 320,577 | |||||||||
| Cash and cash equivalents at end of period | $ | 330,391 | $ | 316,896 | |||||||
| Supplemental disclosure of cash flow information: | |||||||||||
| Interest paid | $ | 40 | $ | 680 | |||||||
| Income taxes paid | $ | 1,019 | $ | 266 | |||||||
(a) Any slight variations in totals are due to rounding.
8
Additional Financial Information
Revenues disaggregated by source:
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | ||||||||||||||||||||||
| (Dollars in Thousands) | 2023 | 2022 | 2023 | 2022 | |||||||||||||||||||
| FFS-patient care | $ | 245,569 | $ | 221,911 | $ | 704,346 | $ | 637,540 | |||||||||||||||
| FFS-administrative services | 29,845 | 25,270 | 83,413 | 71,911 | |||||||||||||||||||
| Capitated revenue | 88,526 | 54,708 | 253,481 | 160,776 | |||||||||||||||||||
| Shared savings | 33,530 | 30,243 | 130,304 | 90,296 | |||||||||||||||||||
| Care management fees (PMPM) | 17,778 | 9,239 | 39,904 | 27,519 | |||||||||||||||||||
| Other revenue | 2,034 | 1,528 | 5,461 | 4,194 | |||||||||||||||||||
| Total Revenue | $ | 417,282 | $ | 342,899 | $ | 1,216,909 | $ | 992,236 | |||||||||||||||
The Company’s liabilities for unpaid medical claims under at-risk capitation arrangements:
| September 30, | ||||||||||||||
| (Dollars in Thousands) | 2023 | 2022 | ||||||||||||
| Balance, beginning of period | $ | 28,617 | $ | — | ||||||||||
| Incurred health care costs: | ||||||||||||||
| Current year | 246,004 | 160,607 | ||||||||||||
| Prior years | 5,723 | — | ||||||||||||
| Total claims incurred | $ | 251,727 | $ | 160,607 | ||||||||||
| Claims paid: | ||||||||||||||
| Current year | $ | (185,287) | $ | (124,385) | ||||||||||
| Prior year | (30,502) | — | ||||||||||||
| Total claims paid | $ | (215,789) | $ | (124,385) | ||||||||||
| Balance, end of period | $ | 64,555 | $ | 36,222 | ||||||||||
9
Key Metrics and Non-GAAP Financial Measures
Privia Health reviews a number of operating and financial metrics, including the following key metrics and non-GAAP financial measures, to evaluate the Company’s business, measure performance, identify trends affecting the Company’s business, formulate business plans, and make strategic decisions.
Key Metrics(a)
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||||||||||||||||||||||||
| (unaudited; $ in millions) | 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||||
Implemented Providers (as of end of period) (1) | 4,105 | 3,595 | 4,105 | 3,595 | ||||||||||||||||||||||
Attributed Lives (as of end of period) (2) | 1,094,000 | 846,000 | 1,094,000 | 846,000 | ||||||||||||||||||||||
Practice Collections (3) | $ | 723.5 | $ | 611.9 | $ | 2,082.4 | $ | 1,789.2 | ||||||||||||||||||
(1) Implemented Providers is defined as the total of all service professionals on Privia Health’s platform at the end of a given period who are credentialed by Privia Health and billed for medical services, in both Owned and Non-Owned Medical Groups during that period. | ||||||||||||||||||||||||||
(2) Attributed Lives are defined as any patient that a payer deems attributed to Privia Health, in both Owned and Non-Owned Medical Groups, to deliver care as part of a Value Based Care arrangement. | ||||||||||||||||||||||||||
(3) Practice Collections are defined as the total collections from all practices in all markets and all sources of reimbursement that the Company receives for delivering care and providing Privia Health’s platform and associated services. Practice Collections differ from revenue by including collections from Non-Owned Medical Groups. | ||||||||||||||||||||||||||
(a) Any slight variations in totals are due to rounding. | ||||||||||||||||||||||||||
Non-GAAP Financial Measures (4)(a)
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||||||||||||||||||||||||
| (unaudited; $ in thousands) | 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||||
| Care Margin | $ | 92,060 | $ | 77,725 | $ | 267,714 | $ | 225,564 | ||||||||||||||||||
| Platform Contribution | $ | 45,181 | $ | 36,981 | $ | 131,199 | $ | 109,451 | ||||||||||||||||||
| Platform Contribution Margin | 49.1% | 47.6% | 49.0% | 48.5% | ||||||||||||||||||||||
| Adjusted EBITDA | $ | 18,774 | $ | 15,650 | $ | 54,950 | $ | 46,587 | ||||||||||||||||||
| Adjusted EBITDA Margin | 20.4% | 20.1% | 20.5% | 20.7% | ||||||||||||||||||||||
(4) In addition to results reported in accordance with GAAP, Privia Health discloses Care Margin, Platform Contribution, Platform Contribution margin, Adjusted EBITDA and Adjusted EBITDA Margin, which are non-GAAP financial measures. Each are defined as follows: •Care Margin is Gross Profit excluding amortization of intangible assets. •Platform Contribution is Gross Profit, excluding amortization of intangible assets, less Cost of platform and excluding stock-based compensation expense included in Cost of platform. •Platform Contribution margin is Platform Contribution divided by Care Margin. •Adjusted EBITDA is net income (loss) attributable to Privia Health Group, Inc. shareholders and subsidiaries excluding non-controlling interests, provision for (benefit from) income taxes, interest income, interest expense, depreciation and amortization, stock-based compensation, employer taxes on equity vesting/exercises, severance charges and other nonrecurring expenses. •Adjusted EBITDA Margin is Adjusted EBITDA divided by Care Margin. | ||||||||||||||||||||||||||
(a) Any slight variations in totals are due to rounding. | ||||||||||||||||||||||||||
10
Reconciliation of Gross Profit to Care Margin(a)
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||||||||||||||||||||||||
| (unaudited; $ in thousands) | 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||||
| Revenue | $ | 417,282 | $ | 342,899 | $ | 1,216,909 | $ | 992,236 | ||||||||||||||||||
| Provider expense | (325,222) | (265,174) | (949,195) | (766,672) | ||||||||||||||||||||||
| Amortization of intangible assets | (1,434) | (842) | (3,883) | (2,509) | ||||||||||||||||||||||
| Gross Profit | $ | 90,626 | $ | 76,883 | $ | 263,831 | $ | 223,055 | ||||||||||||||||||
| Amortization of intangibles assets | 1,434 | 842 | 3,883 | 2,509 | ||||||||||||||||||||||
| Care margin | $ | 92,060 | $ | 77,725 | $ | 267,714 | $ | 225,564 | ||||||||||||||||||
(a) Any slight variations in totals are due to rounding. | ||||||||||||||||||||||||||
Reconciliation of Gross Profit to Platform Contribution(a)
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||||||||||||||||||||||||
| (unaudited; $ in thousands) | 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||||
| Revenue | $ | 417,282 | $ | 342,899 | $ | 1,216,909 | $ | 992,236 | ||||||||||||||||||
| Provider expense | (325,222) | (265,174) | (949,195) | (766,672) | ||||||||||||||||||||||
| Amortization of intangibles assets | (1,434) | (842) | (3,883) | (2,509) | ||||||||||||||||||||||
| Gross Profit | $ | 90,626 | $ | 76,883 | $ | 263,831 | $ | 223,055 | ||||||||||||||||||
| Amortization of intangibles assets | 1,434 | 842 | 3,883 | 2,509 | ||||||||||||||||||||||
| Cost of platform | (50,324) | (43,839) | (145,254) | (127,495) | ||||||||||||||||||||||
Stock-based compensation(5) | 3,445 | 3,095 | 8,739 | 11,382 | ||||||||||||||||||||||
| Platform Contribution | $ | 45,181 | $ | 36,981 | $ | 131,199 | $ | 109,451 | ||||||||||||||||||
(a) Any slight variations in totals are due to rounding. | ||||||||||||||||||||||||||
(5) Amount represents stock-based compensation expense included in Cost of Platform. | ||||||||||||||||||||||||||
Reconciliation of Net Income (Loss) to Adjusted EBITDA(a)
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | |||||||||||||||||||||||||
| (unaudited; $ in thousands) | 2023 | 2022 | 2023 | 2022 | ||||||||||||||||||||||
| Net income (loss) | $ | 5,643 | $ | 1,624 | $ | 20,241 | $ | (26,361) | ||||||||||||||||||
Net income (loss) attributable to non-controlling interests | 299 | (1,068) | (1,537) | (2,551) | ||||||||||||||||||||||
Provision for (benefit from) income taxes | 2,488 | (4,845) | 6,049 | 6,931 | ||||||||||||||||||||||
| Interest (income) expense, net | (2,894) | (285) | (5,524) | 610 | ||||||||||||||||||||||
| Depreciation and amortization | 1,731 | 1,153 | 4,761 | 3,436 | ||||||||||||||||||||||
| Stock-based compensation | 10,801 | 14,833 | 25,429 | 58,184 | ||||||||||||||||||||||
Other expenses(6) | 706 | 4,238 | 5,531 | 6,338 | ||||||||||||||||||||||
| Adjusted EBITDA | $ | 18,774 | $ | 15,650 | $ | 54,950 | $ | 46,587 | ||||||||||||||||||
(a) Any slight variations in totals are due to rounding. | ||||||||||||||||||||||||||
(6) Other expenses include employer taxes on equity vesting/exercises, legal, severance and certain non-recurring costs. Employer taxes on equity vesting/exercises of $0.3 million and $2.2 million were recorded for the three months ended September 30, 2023 and 2022, respectively. Employer taxes on equity vesting/exercises of $1.5 million and $2.8 million were recorded for the nine months ended September 30, 2023 and 2022, respectively. | ||||||||||||||||||||||||||
11
Reconciliation of Net Income (Loss) to Adjusted Net Income and Adjusted Net Income Per Share(a)
| For the Three Months Ended September 30, | For the Nine Months Ended September 30, | ||||||||||||||||||||||
| (unaudited; $ in thousands) | 2023 | 2022 | 2023 | 2022 | |||||||||||||||||||
| Net income (loss) | $ | 5,643 | $ | 1,624 | $ | 20,241 | $ | (26,361) | |||||||||||||||
| Stock-based compensation | 10,801 | 14,833 | 25,429 | 58,184 | |||||||||||||||||||
| Intangible amortization expense | 1,434 | 842 | 3,883 | 2,509 | |||||||||||||||||||
Provision for (benefit from) income tax | 2,488 | (4,845) | 6,049 | 6,931 | |||||||||||||||||||
Other expenses(6) | 706 | 4,238 | 5,531 | 6,338 | |||||||||||||||||||
Adjusted net income attributable to Privia Health Group, Inc. | $ | 21,072 | $ | 16,692 | $ | 61,133 | $ | 47,601 | |||||||||||||||
| Adjusted net income per share attributable to Privia Health Group, Inc. stockholders – basic | $ | 0.18 | $ | 0.15 | $ | 0.53 | $ | 0.43 | |||||||||||||||
| Adjusted net income per share attributable to Privia Health Group, Inc. stockholders – diluted | $ | 0.17 | $ | 0.13 | $ | 0.49 | $ | 0.39 | |||||||||||||||
| Weighted average common shares outstanding – basic | 117,602,059 | 111,592,834 | 116,266,938 | 109,458,855 | |||||||||||||||||||
| Weighted average common shares outstanding – diluted | 124,924,442 | 124,845,602 | 124,646,849 | 122,741,319 | |||||||||||||||||||
(a) Any slight variations in totals due to rounding. | |||||||||||||||||||||||
(6) Other expenses include employer taxes on equity vesting/exercises, legal, severance and certain non-recurring costs. Employer taxes on equity vesting/exercises of $0.3 million and $2.2 million were recorded for the three months ended September 30, 2023 and 2022, respectively. Employer taxes on equity vesting/exercises of $1.5 million and $2.8 million was recorded for the nine months ended September 30, 2023 and 2022, respectively. | |||||||||||||||||||||||
12